Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Period	TotalRevenue
2018-09-30	$1.41M
2019-12-31	$2.91M
2020-12-31	$1.72M
2021-12-31	$2.33M
2022-12-31	$6.36M
2023-12-31	$1.70M
2024-12-31	$10.12M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AUTL	$1.49	+9.56%	1.67M
3
4
5

Autolus Therapeutics plc (AUTL) Revenue History

Revenue Data

Get Autolus Therapeutics plc Data in Excel

More AUTL Financial Data